PRESS RELEASE: Shionogi-ViiV Healthcare LLC -2-

22nd Jul 2010 13:45

GlaxoSmithKline disclosure notice: Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2009. Pfizer disclosure notice: Pfizer assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments. This release contains forward-looking information about Pfizer, GlaxoSmithKline and ViiV Healthcare and about the prospects of the companies, including revenues from in-line products and the potential benefits of product candidates that will be contributed to that company, as well as the potential financial impact of the transaction. Such information involves substantial risks and uncertainties including, among other things, decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates; and competitive developments. A further list and description of risks and uncertainties can be found in Pfizer's Annual Report of Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K. Shionogi forward-looking statement: This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. This announcement contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations nor provide medical advice of any kind. SOURCE Shionogi-ViiV Healthcare LLC /CONTACT: UK Media inquiries: Rebecca Hunt, +020-8380-6275, or Claire Brough, +020-8047-5502; or US Media inquiries: Marc Meachem, +1-919-483-5005; or GSK European Analyst/Investor inquiries: David Mawdsley, +020-8047-5564, or Sally Ferguson, +020-8047-5543, or Gary Davies, +020-8047-5503; or GSK US Analyst/ Investor inquiries: Tom Curry, +1-215-751-5419, or Jen Hill Baxter, +1-215-751-7002; or Shionogi & Co., Ltd. Enquiries, Corporate Communications, +81-6-6209-7885 /Web site: http://www.shionogi.co.jp Order free Annual Report for GlaxoSmithKline plc Visit http://djnweurope.ar.wilink.com/?ticker=GB0009252882 or call +44 (0)208 391 6028 (END) Dow Jones Newswires July 22, 2010 08:45 ET (12:45 GMT)